“…Gpl20 can induce several kinds of immune dysfunction observed in HIV-1-infected patients such as CD4 down-modulation on T cells, T-cell activation, and T-cell anergy (shown as human leukocyte antigen [HLA]-class II molecule expression on T cells, low production of mitogen-induced interleukin [IL]-2, and a weak response in the mixed lymphocyte reaction), polyclonal B-cell activation, and apoptotic death of CD4+ T cells (5,7,14,23,26,28,36,41,43,44). These immune abnormalities have been reported to be mediated by several cytokines, such as tumor necrosis factor (TNF)-a, IL-6, and IL-10 produced from gpl20-stimulated macrophages (7,23,26,28,36,41,43,44,46), and to be mediated by phosphorylation of protein tyrosine kinase p56lck in CD4+ cells induced by binding of HIV-1 envelope glycoprotein (19,21). Although such immunologie changes are seen with HIV-2 infection, they are less severe than would be expected with HIV-1 infection in similar crosssectional settings (29).…”